Comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 vs 3mc Syndrome 2 C0796279
Clinical comparison between 3 Methylcrotonyl Coa Carboxylase 1 Deficiency CN028786 and 3mc Syndrome 2 for differential diagnosis and treatment planning.
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
A metabolic disorder affecting the processing of leucine, an amino acid. Symptoms may include developmental delay, low blood sugar, and feeding problems. Dietary restrictions and supplementation are typically used in management.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
0-null
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
metabolic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
3-methylcrotonyl-coa-carboxylase-1-deficiency-CN028786 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Developmental concerns | May occur alongside feeding problems or low blood sugar. | May accompany congenital facial and growth manifestations. | Moderate |
| Metabolic instability | Low blood sugar and feeding problems may reflect impaired leucine processing. | Not described as a primary metabolic presentation in the supplied data. | High |
| Congenital physical pattern | No characteristic facial or growth pattern is established here. | Facial, developmental, and growth manifestations are described. | High |
When to favor each condition
Choose 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 when
Leucine-processing concern
The source describes a metabolic disorder affecting leucine rather than a malformation syndrome.
Moderate
Low blood sugar or feeding problems
These possible features support metabolic evaluation, but do not confirm the diagnosis.
Moderate
Diet or supplementation is central
Source management typically uses dietary restriction and supplementation under specialist care.
Moderate
Choose 3mc Syndrome 2 C0796279 when
Features present from birth
The right onset is coded at birth, whereas left onset data are incomplete.
Moderate
Facial and growth manifestations
These multisystem congenital features match the supplied description of 3MC syndrome 2.
Moderate
Supportive symptom management
The source emphasizes symptom management rather than metabolic dietary therapy.
Low
How key tests differ
| Test | 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Blood glucose during illness | Low blood sugar may occur; no cutoff is supplied. | No expected glucose abnormality is established. | An abnormal glucose result is a finding, not a diagnosis. |
| Leucine-pathway metabolic testing | May be used to assess leucine processing; analytes and cutoffs are not supplied. | No characteristic metabolic abnormality is established by the source. | Results require specialist correlation and do not alone prove either condition. |
| Genetic and clinical syndrome evaluation | May support a metabolic diagnosis, but no gene is named here. | May support a congenital syndrome, but no gene is named here. | Testing should be interpreted by clinicians in the full clinical context. |
Prognosis comparison
3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786
- Outcome
- Long-term outcome is not established; the source labels severity as severe.
- Factors
- Glucose stability, feeding, and development may matter, but effects are unquantified.
3mc Syndrome 2 C0796279
- Outcome
- Long-term outcome is not established; the source labels severity as moderate.
- Factors
- The extent of facial, developmental, and growth manifestations may influence needs.
Time frame: Both are described as chronic, but precise timelines are unavailable.
Etiology and severity labels differ; prognosis must be individualized by clinicians.
Complications comparison
| Complication | Presentation |
|---|---|
| Low-blood-sugar complications | Possible when hypoglycemia occurs; frequency is not established. Not described in the supplied data. Risk and prevention require individualized clinical assessment. |
| Developmental delay | May occur in the metabolic disorder. May occur with other congenital manifestations. The symptom can overlap, but its context differs. |
| Feeding or growth difficulty | Feeding problems are described. Growth manifestations are described. Neither severity trajectory nor frequency is quantified. |
Patient education highlights
- HighUrgent warning symptoms
Seek urgent care for poor feeding, unusual sleepiness, or suspected low blood sugar. This comparison cannot guide emergencies.
- MediumResult versus diagnosis
An abnormal test result is not itself a diagnosis and needs clinician interpretation.
- MediumIndividualized management
Diet, supplements, or supportive care should be clinician-directed. No doses are provided here.